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Abstract
Reproductive health has been deleteriously affected by poor quality medicines. Emergency contraceptive pills (ECPs) are an
important birth control method that women can use after unprotected coitus for reducing the risk of pregnancy. In
response to the detection of poor quality ECPs commercially available in the Peruvian market we developed a tiered multi-
platform analytical strategy. In a survey to assess ECP medicine quality in Peru, 7 out of 25 different batches showed
inadequate release of levonorgestrel by dissolution testing or improper amounts of active ingredient. One batch was found
to contain a wrong active ingredient, with no detectable levonorgestrel. By combining ultrahigh performance liquid
chromatography-ion mobility spectrometry-mass spectrometry (UHPLC-IMS-MS) and direct analysis in real time MS (DART-
MS) the unknown compound was identified as the antibiotic sulfamethoxazole. Quantitation by UHPLC-triple quadrupole
tandem MS (QqQ-MS/MS) indicated that the wrong ingredient was present in the ECP sample at levels which could have
significant physiological effects. Further chemical characterization of the poor quality ECP samples included the
identification of the excipients by 2D Diffusion-Ordered Nuclear Magnetic Resonance Spectroscopy (DOSY 1H NMR)
indicating the presence of lactose and magnesium stearate.
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Introduction
Over the last decade, there has been increasing interest and
concern regarding the quality of medicines worldwide, stimulating
research into their epidemiology and novel detection methods.
Much of this work has focused on antimalarials [1,2] but there is
evidence that poor quality antibiotics and anti-tuberculosis drugs
are focally common. Recent cases of poor quality medicines
include contaminated isosorbide mononitrate, which led to 125
deaths in Pakistan [3]; anti-visceral leishmaniasis medications
found in Bangladesh that did not contain any of the expected
active pharmaceutical ingredient (API) miltefosine [4]; and
contaminated methylprednisolone injections that led to an
epidemic of fungal infections in the US [5]. Poor quality medicines
have a wide range of public health impacts, ranging from poor
outcomes, including treatment failure and even death; economic
consequences for patients, for the society, and the legitimate
pharmaceutical industry; and engendering drug resistance.
Therefore, assessing the prevalence of poor quality drugs is an
essential step in protecting the welfare of patients.
There are three main categories of poor quality medicines: i)
substandard medicines, resulting from negligent or unintentional
factory error; ii) falsified medicines, which arise from fraudulent,
criminal production; and iii) degraded medicines, which result
from deterioration after factory production such as poor storage
conditions; e.g. heat, humidity, etc. Because of intellectual property
connotations, the term counterfeit is being replaced with the term
falsified that is devoid of such considerations, although the precise
definition of these terms has yet to be agreed globally [6,7].
Falsified drugs may not contain the active ingredient, may contain
wrong ingredients or may even contain toxic compounds.
Substandard medicines usually contain less than the stated active
ingredient [8].
There are diverse techniques to analyze pharmaceuticals and
identify poor quality medicines [9,10]. Typically, visual inspection
of product and packaging is performed first to identify salient
differences with the genuine product; this is followed by tests for
physical properties such as disintegration, reflectance spectrosco-
py, or refractive index; and chemical tests that include colorimetry,
dissolution, thin layer chromatography (TLC) and liquid chroma-
tography with spectrophotometric detection. The investigation of
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poor quality medicines that lack the expected API but may instead
contain a different compound requires the use of near infrared
(NIR), Raman, UV-visible spectroscopy, or even more sophisti-
cated analytical techniques such as nuclear magnetic resonance
spectroscopy (NMR) or mass spectrometry (MS).
Reproductive health has been affected by poor quality health
products such as falsified hormonal contraceptives and poor
quality condoms [11]. In 1998, counterfeit contraceptive pills were
reported in Brazil [12]; in 2004, the US FDA warned the public
about an internet site selling counterfeit contraceptive transdermal
patches [13]. More recently, the US FDA issued an alert of a
potentially-ineffective and suspect falsified emergency contracep-
tive labeled as Evital [14], and the World Health Organization
(WHO) warned of falsified ‘Postinor 2’ (levonorgestrel 0.75 mg) in
Nigeria (150,000 doses), Ghana, Kenya and Angola, containing no
detectable levonorgestrel [15].
Emergency contraceptive pills (ECPs) are an important birth
control method that women can use after unprotected coitus [16].
In the US, more than 5 million women aged 15–44 years used
emergency contraception between 2006 and 2010 [17]. There are
over 150 different brands of ECPs containing levonorgestrel,
mifepristone, or ulipristal acetate available globally, which are
manufactured in over 25 countries [18]. In South American
countries, a wide variety of registered ECP brands exists. Peru has
over 20 brands in the market that are manufactured in 10 different
countries [18]. With the high number of ECP brands and source
countries, this may increase the risk of substandard, degraded or
falsified products. The unwitting use of poor quality ECPs may
result in unwanted pregnancy, and diverse medical and social
consequences.
This work presents the first report on a multi-platform analytical
strategy used to investigate suspect poor quality ECPs found
through a small survey conducted in the Peruvian market.
Materials and Methods
Sample collection
Samples of levonorgestrel tablets (0.75 mg and 1.5 mg) were
purchased at 15 pharmacies and pharmaceutical distributors in
Lima, Peru, using a convenience sampling method [9]. At least 60
tablets were purchased per sample, consisting of the same batch
number for a given brand. For each sample, the brand name,
manufacturer, lot number, number of tablets/blister packs
purchased, manufacturing date, expiration date, date purchased,
purchaser and address of purchase were recorded. Tablets were
collected from 25 different product batches encompassing 20
brands labeled as manufactured in nine countries (Argentina,
Chile, China, Colombia, Hungary, India, Pakistan, Peru, and
Uruguay). Photographs were taken of the front and back of the
outer packaging and blister packs. Results are reported, as far as
possible, according to the Medicine Quality Assessment Reporting
Guidelines (MEDQUARG) [19].
Chemicals
Omnisolv LC-MS grade acetonitrile and hydrochloric acid 37%
were purchased from EMD (Billerica, MA, USA). LC-MS grade
methanol was purchased from J.T. Baker Avantor Performance
Materials, Inc. (Center Valley, PA, USA). HPLC grade cyclohex-
ane and acetone were purchased from Alfa Aesar (Ward Hill, MA,
USA); HPLC grade acetonitrile and methanol were purchased
from Honeywell Burdick & Jackson (Morristown, NJ, USA).
Ethanol (190 proof) was obtained from Decon Labs, Inc. (King of
Prussia, PA, USA). Ultrapure water, with 18.2 MV cm resistivity
(Hydro Pico Pure system and Barnstead Nanopure UV ultrapure
water system, USA) was used to prepare solutions and mobile
phases. Levonorgestrel (99.9%) and ethinyl estradiol (99.9%) were
purchased through the EDQM/WHO International Chemical
Reference Substances program, and norgestrel (99.7%) was
purchased from the US Pharmacopeia. Sulfamethoxazole stan-
dard (ACS reagent $99%), methanol-d4 (CD4O, 99.8 atom% D),
and deuterium oxide (D2O 99.9 atom% D) were purchased from
Sigma-Aldrich Co. (St. Louis, MO, USA). Ammonium acetate
(HPLC $99.0%) was purchased from Fluka Chemical Corp.
(Milwaukee, WI, USA). Sodium dodecyl sulfate was purchased
from BioRad (Hercules, CA, USA); c-cyclodextrin (c-CD) was
purchased from Wacker (Mu¨nchen, Germany). PTFE syringe
filters, 0.45 mm were purchased from VWR (Radnor, PA, USA)
and Silica gel 60 20620 cm, 250 mm thickness TLC plates were
purchased from EMD (Billerica, MA, USA).
Thin Layer Chromatography (TLC) analysis [20]
TLC analysis was conducted with 10 mL applications of
standards and samples using a mobile phase of cyclohexane:ace-
tone 70:30 v/v with observation using 254 nm light. Samples were
prepared by dissolving a mass of powdered tablets equivalent to
1.5 mg of levonorgestrel in 5 mL of acetonitrile, followed by
filtration. Standards of 0.3 mg mL21 levonorgestrel RS were
prepared in acetonitrile.
High Performance Liquid Chromatography with Diode
Array Detection (HPLC-DAD)
HPLC-DAD was used to determine the limit of dextronorges-
trel, related substances, to perform the content uniformity assay,
and analyze standards and samples from dissolution tests,
following the International Pharmacopeia specifications for
levonorgestrel tablets [20]. HPLC-DAD analysis was conducted
with an Agilent HP1200 consisting of a G1329A autosampler, a
G1322A degasser, a G1311A quaternary pump, a G1316A
column thermostat, and a G1315B diode array detector (Agilent
Technologies, Santa Clara, CA, USA). Data was acquired using
ChemStation software (Agilent Technologies). Specific details for
each assay are provided below.
Limit of Dextronorgestrel. Chiral HPLC was utilized to
quantify the level of dextronorgestrel, while verifying the presence
of levonorgestrel. HPLC was conducted on a Hypersil ODS 2 C18
column (15 cm64.6 mm, 5 mm particle size, Waters Corporation,
Milford, MA, USA). The chromatographic method used an
isocratic mobile phase of methanol: water with 1% (w/w) c-CD
50:50 v/v. The flow rate was 1.5 mL min-1 and the injection
volume was 20 mL. The detection was performed by monitoring
absorbance at 242 nm. For preparing test samples with 0.12 mg
mL21 of levonorgestrel (D1), an amount of powdered tablet
(equivalent to 3 mg of levonorgestrel) was transferred to a 25.0 mL
volumetric flask with 15 mL of methanol:water 80:20 v/v
(diluent), heated at 60uC for 10 minutes (with periodic shaking),
brought to volume with diluent, and filtered through a 0.45-mm
filter. Test samples D1were then diluted to reach 6 mg mL21 of
levonorgestrel (D2). A norgestrel standard (N) was prepared at
12 mg mL21 norgestrel RS in diluent. A levonorgestrel standard
(L1) was prepared at 6 mg mL21 levonorgestrel RS in diluent, and
diluted to 0.12 mg mL21 in diluent (L2). Standard N was used to
designate the retention time for dextronorgestrel and levonorges-
trel, requiring a resolution of at least 1.5. Identification of
levonorgestrel was conducted through retention time matching
between the standard L1 and test sample D2. Quantification of
dextronorgestrel was obtained from injections of standard L2 and
test sample D1. To yield full compliance with the International
Pharmacopeia specifications [20] for the limit of dextronorgestrel,
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the chromatographic peak area for dextronorgestrel in D1 should
not be greater than that of levonorgestrel in L2 at 0.1%.
Related Substances. Samples were analyzed by HPLC-
DAD using a Spherisorb ODS 2 C18 column (25 cm64.6 mm,
5 mm particle size, Waters Corporation, Milford, MA, USA). An
isocratic mobile phase of methanol:acetonitrile:water 15:35:50 v/v
was used in the chromatographic method with a flow rate of
1.2 mL min21. The column temperature was set at 30uC, and the
volume of injection was 100 mL. The detection was performed by
monitoring absorbance at 220 nm. Test samples (RS1) were
prepared by transferring a quantity of powdered tablets equivalent
to 0.18 mg of levonorgestrel in 5 mL of diluent (50% v/v
methanol in water). These were sonicated for 30 minutes, stirred
for 15 minutes, centrifuged (4000 RPM, 10 min), and the
supernatant was separated for analysis. Test samples (RS2) were
prepared by diluting RS1 to 0.36 mg mL21 of levonorgestrel in
diluent. A standard of 4 mg mL21 ethinyl estradiol and levonor-
gestrel was injected to ensure that a resolution of at least 12 could
be obtained between the two compounds. With injections of RS1
and RS2, the area of any peak from RS1 (other than
levonorgestrel) should not be greater than the area of levonorges-
trel in RS2 (or greater than a level of 1.0% relative to
levonorgestrel). Also from RS1, the sum of areas of all peaks
(other than levonorgestrel) should not be greater than twice the
area of levonorgestrel in RS2 (or greater than a level of 2.0%
relative to levonorgestrel).
Assay/Content Uniformity. Samples were analyzed with
HPLC using a Spherisorb ODS 2 C18 column (15 cm64.6 mm,
5 mm particle size, Waters Corporation, Milford, MA, USA). An
isocratic mobile phase of acetonitrile:water 50:50 v/v was used in
this chromatographic method with a flow rate of 1.3 mL min21.
The column was held at ambient temperature, the volume of
injection was 25 mL, and the detection was at 220 nm. Test
samples were prepared by transferring one powdered tablet to an
enclosed test tube with 5.0 mL of mobile phase. The suspension
was sonicated for 45 minutes, shaken for 15 minutes, and
centrifuged (4000 RPM, 10 min). The supernatant was further
diluted to a theoretical concentration of 6 mg mL21 of levonor-
gestrel. Standards of 6 mg mL21 levonorgestrel RS prepared in
mobile phase were used to determine the amount of levonorgestrel
in test sample injections. Assay and content uniformity were
judged from the % label claim values of API found for individual
tablets. Unless indicated otherwise, 10 tablets were analyzed per
test sample. The assay requires the average to be within 90.0%–
110.0% of the label claim. For content uniformity, each of 10
tablets should contain within 615% of the average amount. If one
individual tablet deviates by more than615% but is within625%
of the average amount, another group of 20 tablets are tested. No
more than one tablet out of 30 can deviate by more than 615% of
the average amount and none should deviate by more than 625%
of the average amount.
Dissolution Test. Analysis was conducted with a VK 7000
Varian dissolution apparatus (VanKel Technology Group, Cary,
NC, USA) with paddles rotating at 75 rpm in 500 mL of medium
comprised of 0.1% sodium dodecyl sulfate in a 0.1 M HCl
aqueous solution. A sample aliquot of 10 mL was centrifuged
(4000 RPM, 10 min) 30 min after dropping the individual tablets
in the vessels, and the supernatant was used for analysis. Standards
were prepared by dissolving 30 mg of levonorgestrel RS in 50 mL
of ethanol via sonication, and further dilution in dissolution
medium to a final concentration of 6 mg mL21. Standards and test
samples were analyzed under the same HPLC conditions utilized
for the assay/content uniformity. The testing protocol was
conducted in a series of stages, proceeding to the next stage only
if a given stage was non-compliant. Tablets were evaluated based
on the percentage of released API relative to the theoretical
amount in the tablet. The criteria utilized for each stage in the
testing protocol was as follows: Stage 1= individual values of 6
tablets must be greater than or equal to 80%, Stage 2= mean
value of 12 tablets must be greater than or equal to 75%, and no
tablets can be less than 60%, Stage 3= mean value of 24 tablets
must be greater than or equal to 75%, no more than 2 tablets can
be less than 60%, and no tablet can be less than 50%.
Direct Analysis in Real Time-Mass Spectrometry and
Tandem Mass Spectrometry (DART-MS and DART MS/MS)
MS screening was performed with a commercial DART-100
ion source (IonSense, Inc., Saugus, MA, USA) coupled to a
quadrupole-time of flight (Q-TOF) mass spectrometer (Bruker
micrOTOF-Q I; Bremen, Germany) through a VAPUR
interface. The VAPUR interface was designed to accommo-
date for the gas flow of the DART source and consists of a
custom gas-ion separator tube (GIST; IonSense Inc. Saugus,
MA, USA) connected to a Vacuubrand 2 C diaphragm pump
(Vacuubrand, Wertheim, Germany), the outlet of which is
connected to an exhaust line. The ion source exit, interface
inlet and mass spectrometer inlet are aligned along the same
axis. Ions created between the ion source exit and the interface
inlet (ionization region), are dragged into the mass spectrom-
eter by the suction created by the diaphragm pump and the
vacuum system of the mass spectrometer. By partially
removing unionized molecules and plasma gases from the
dragged plume, the interface also serves to reduce the vacuum
load on the first differentially pumped region of the mass
spectrometer and maintain the instrument’s pressure require-
ments for operation. The DART ion source was operated with
helium (UHP 99.999%, Airgas, Atlanta, GA, USA) at a 1 L
min21 flow rate and at 150uC gas temperature. Potentials of 2
3500 V, +200 V, and +150 V were applied at the needle
electrode, discharge grid, and exit grid of the ion source,
respectively. The mass spectrometer settings were as follows:
end plate offset 2500 V, capillary 22000 V, dry gas (nitrogen)
1.2 L min21, dry gas temperature 150uC, spectra acquired at
1 Hz in the 50–1200 m/z range. A methanol solution of a
50:50 mixture of polyethylene glycol 400 and 600 (PEG, Sigma
Aldrich, St. Louis, MO, USA) was used as the mass calibration
standard. The mass spectrometer provided a mass resolving
power of ,12,000 m/Dm at m/z 393.2095 and ,9000 m/Dm
at m/z 151.0964, and a typical mass accuracy of 2–5 ppm was
obtained for acetaminophen as test compound. All experi-
ments were performed in positive-ion detection mode and all
samples were analyzed under identical instrumental and
experimental conditions. For analysis, a few particles of each
tablet were deposited on a glass capillary by rubbing the tablet
dust on the capillary. Two different tablets from sample 2a and
levonorgestrel-containing ECPs as well as standards were
analyzed in technical triplicates. The capillary with the
deposited sample was introduced in front of the plasma plume
exiting the DART source for sample ionization and subsequent
detection by the mass spectrometer. Tandem MS collision
induced dissociation experiments were performed to confirm
the identity of analyte peaks detected in the mass spectrometer.
High purity nitrogen (99.998%) was used as the collision gas.
Mass spectral data processing was performed using Bruker
Daltonics Data Analysis Version 4.0 software.
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Ultra High Performance Liquid Chromatography-Ion
Mobility Spectrometry-Mass Spectrometry and Tandem
Mass Spectrometry (UHPLC-IMS-MS, UHPLC-MS/MS)
A measured mass of each tablet was dissolved in 15 mL of LC-
MS grade methanol, and sonicated for 30 min, 5 mL of nanopure
water were added to help solubilization, and methanol was finally
added to complete 25.0 mL final volume. The sample was vortex-
mixed for 2 min, centrifuged (3 min, 13,0006g), and the
supernatant was then 10-fold diluted for UHPLC-IMS-MS and
UHPLC-MS/MS analysis. Standards of levonorgestrel and
sulfamethoxazole were prepared in methanol:water 80:20 v/v.
UHPLC-IMS-MS analysis was performed using a Waters
ACQUITY Ultra Performance LC (Waters Corporation, Man-
chester, UK) system, coupled to a Synapt G2 High Definition
Mass Spectrometry system (Waters Corporation, Manchester,
UK), which is a hybrid quadrupole-ion mobility-orthogonal
acceleration time-of-flight instrument, with typical resolving power
of 20,000 m/Dm (FWHM) and mass accuracy of 9 ppm at m/z
556.2771. The UHPLC system was fitted with a Waters
ACQUITY UPLC BEH C18 column (1.06100 mm, 1.7 mm
particle size, Waters Corporation, Milford, MA, USA). The
optimized traveling wave ion mobility spectrometry (TWIMS)
conditions were as follows: wave height ramped between 8 and
20 V; wave velocity ramped between 300 and 600 m s21; IMS gas
flow rate: 90 mL min21; helium gas flow rate: 180 mL min21.
The instrument was operated in positive ion mode with a probe
capillary voltage of 3 kV, and a sampling cone voltage of 45 V.
The source and desolvation temperatures were set to 120uC and
250uC, respectively; and the nitrogen desolvation flow rate was set
to 650 L h21. The mass spectrometer was calibrated across the
50–1200 m/z range using a 0.5 mM sodium formate solution
prepared in 90:10 2-propanol:water v/v. Data were mass
corrected during acquisition using a leucine encephalin (m/z
554.2615) reference spray (LockSpray) infused at 2 mL min21. The
scan time was set to 1 s. Data acquisition and processing was
carried out using MassLynx v4.1 and Drift Scope v2.1 (Waters
Corp.). The chromatographic method involved elution with
acetonitrile (mobile phase A) and water with 0.1% acetic acid
(mobile phase B) using the following gradient duration program:
0–4 min 10% A; 4–5 min 10–100% A; 5–5.4 min 100–10% A;
5.4–6 min 10% A. The flow rate was 0.3 mL min21, and the
column temperature was 45uC. The autosampler tray temperature
was set to 5uC, the injection volume was 5 mL and the total run
time was set to 6 min. Two different tablets from sample 2a and
standards were analyzed in technical triplicates.
UHPLC-MS/MS analysis was performed with a 1290 Infinity
UHPLC unit coupled to a 6430 Triple Quadrupole LC-MS
system (both Agilent Technologies, Santa Clara, CA, USA) using
an identical column and chromatographic conditions as those
described above for UHPLC-IMS-MS analysis. Ultrahigh purity
nitrogen ($99.999%) was used as the collision gas. The Q1 and
Q3 quadrupoles were set to unit resolution. Data acquisition and
processing were carried out using Mass Hunter B.04.01 software
(Agilent Technologies, Santa Clara, CA, USA). For sulfamethox-
azole MS/MS experiments, the instrument was operated in
positive electrospray ion mode with a capillary voltage of 4 kV.
The nebulizer pressure was set to 25 psi; the desolvation gas
temperature to 350uC, and the nitrogen flow rate to 10 L min21.
Two different tablets from sample 2a were analyzed for
quantitation of sulfamethoxazole. At least 10 points were acquired
across chromatographic peaks to ensure proper quantitation.
Three technical replicates for standard solutions and sample 2a
were analyzed. The standard deviation (SD) of each calibration
point was observed to statistically increase with concentration
(two-sided F-test, p = 0.05). Therefore, weights (w i = si
22) were
used to account for heteroscedasticity, where si is the SD of the
different technical replicates.
1H and 2D DOSY 1H NMR analysis
Samples were prepared by dissolving a mass of powdered tablets
equivalent to 5 mg of analyte in 0.7 mL of methanol-d4:deuterium
oxide 80:20 v/v, followed by sonication for 30 minutes, and
centrifugation (3 min, 13,0006g). The supernatant was poured
into a 5-mm NMR tube for analysis. Individual standards of
lactose, magnesium stearate, levonorgestrel, and sulfamethoxazole
were prepared in the same deuterated solvent mixture reaching
final concentrations of 7 mg mL21. NMR experiments were
performed in duplicate at a temperature of 298 K on a Bruker-
Biospin Avance II 500 NMR spectrometer, operated at a 1H
frequency of 500 MHz. The instrument was equipped with a
5 mm 1H/X-broadband probe with gradient in the z-direction.
Acquisition parameters for the 1D 1H NMR experiments
comprised 1H excitation with a 30 degree pulse followed by an
acquisition of 65536 data points during a time of 3.17 s; and
followed by a recycle delay of 1 s. A total of 16 scans were
accumulated. Data were referenced with respect to the solvent
peak of the deuterated solvent (methanol-d4 at 3.31 ppm). The
parameters for 2D DOSY 1H NMR experiments were as follows:
LED pulse sequence with bipolar gradients, D=50 ms diffusion
time, d=2.2 ms gradient duration; 2s repetition delay, and 16
averages. Diffusion was encoded using gradient pulses with a
sinusoidal shape with 16 gradient steps ranging from 0.7 to 32
Gauss cm21. All NMR data were processed using TOPSPIN
software (Bruker).
Results
Full compliance with the International Pharmacopeia specifi-
cations for levonorgestrel tablets [20] was observed for 18 of 25
ECP samples (72%, Table 1). For the seven non-compliant
samples, five failed dissolution testing, with samples 2c, 3b, 4, and
6 giving dissolution results ranging from 57.8% to 73.0%
(minimum acceptable limit of 75%). Sample 10 gave no release
of levonorgestrel, while also exhibiting poor results for related
substances (unspecified impurities) and content uniformity. In
addition, samples 2c and 17 revealed poor content uniformity with
a wide range of levonorgestrel levels between tablets.
The most worrisome result was found for sample 2a, with no
evidence of levonorgestrel in any of the assays conducted. The lack
of API was first suggested by the TLC assay against a
levonorgestrel standard and a positive control (Figure 1). This
result was confirmed by HPLC-DAD, which also suggested the
presence of a different compound in the tablet, eluting at a shorter
retention time than levonorgestrel (Figure 2). In order to further
investigate the composition of this sample, UHPLC-IMS-MS was
conducted. First, a levonorgestrel standard was analyzed to
establish the retention time, the drift time and the mass spectral
features of the correct API. Figures 3a–b illustrate the extracted
ion chromatogram and the extracted ion mobility chronogram for
the [levonorgestrel+H]+ ion at m/z 313.2168 obtained for a
10 mM standard, which exhibited a retention time and drift time of
2.75 min and 4.21 ms, respectively. Under identical conditions, no
peak was observed in the extracted ion chromatogram and ion
mobility chronogram of sample 2a. Instead, the base peak in the
chromatogram of the suspicious sample was given by a compound
that eluted at 1.55 min, with a monoisotopic m/z of 254.0598.
Assuming that the peak of interest in the spectrum corresponded
to the [M+H]+ ion, elemental formulae were generated based on
Poor Quality Emergency Contraceptives in Peru´
PLOS ONE | www.plosone.org 4 April 2014 | Volume 9 | Issue 4 | e95353
the expected mass accuracy and experimental isotopic pattern,
and the possible candidate molecules were searched against the
Metlin database [21]. In this way, the wrong API in sample 2a was
identified as the antibiotic sulfamethoxazole and confirmed by
UHPLC-IMS-MS analysis of a sulfamethoxazole standard.
Figures 3c–d show the extracted ion chromatogram, and the
extracted ion mobility chronogram for the [sulfamethoxazole+H]+
ion at m/z 254.0599 obtained for a 10 mM standard, which
exhibited a retention time and drift time of 1.561min and 3.02 ms,
respectively. The extracted ion chromatogram, and the extracted
ion mobility chronogram for the [sulfamethoxazole+H]+ ion in
sample 2a, as well as the corresponding mass spectrum for the
target compound, are shown in Figures 3e–f. These results
highlight the retention time, drift time, and isotopic pattern
matches for the sulfamethoxazole standard and the poor quality
ECP. The high resolving power of the time-of-flight analyzer
combined with the separation provided by the chromatographic
method and ion mobility stage allowed the identification of the
main active ingredient in sample 2a. The orthogonality between
IMS and MS separations increased the peak capacity of MS alone,
providing information-rich data that contributed to the identifi-
cation of the wrong API in the ECP.
Further confirmation of the presence of sulfamethoxazole in
sample 2a was accomplished by DART-MS and MS/MS, which
provides an ionization mechanism which is complementary to
those in electrospray ionization [22]. Samples were analyzed with
no need of solvents, extractions, processing, or preparation steps
by holding a capillary with sample deposited on it in front of the
atmospheric pressure inlet of the high resolution mass spectrom-
eter while exposing it to the ionizing plasma. The resulting spectra
were obtained in seconds. Figure 4a illustrates the mass spectrum
of an authentic levonorgestrel-containing ECP from an authentic
sample of the same brand/manufacturer as compared to the
packaging for sample 2a except that the tablet strength was
0.75 mg (we were unable to obtain an authentic sample of the
authentic 1.5 mg product), which exhibited the expected signal for
the [levonorgestrel+H]+ ion at m/z 313.2419 (Dm=25.1 mDa).
Further fragmentation of this ion provided a unique mass spectral
Table 1. Summary of results for the ECP quality surveya.
API Level Product Code - Expiration Date Dissolution (Stage; AVG)b Related Substancesc Assay-CUd (Min. – Max.)
1.5 mg 1 - Feb 2016 S2; 80.1 S-0.1%, T-0.6% 100.0; 97.7–102.4
2a - May 2015 NC NC NC
2b - Aug 2016 S2; 77.4 S-0.3%, T-1.0% 95.1; 82.2–103.4
2c – Dec 2016 S3; 58.5 S-0.4%, T-1.3% 96.2; 85.4–136.6
3a - Oct 2015 S1; 94.3 S-0.4%, T-1.1% 101.3; 100.5–102.6
3b - Dec 2016 S3; 73.0 S-0.6%, T-1.8% 97.6; 90.0–105.7
4 - Oct 2014 S1; 59.6e S-0.9%, T-1.5% 96.7; 93.3–98.0
5a - Dec 2013 S1; 93.8 S-0.4%, T-1.4% 97.3; 96.5–98.6
5b - Nov 2013 S1; 98.2 S-0.3%, T-1.4% 97.0; 88.2–99.5
6 - Apr 2014 S3; 57.8 S-0.3%, T-1.3% 99.0; 92.9–102.6
7 - Oct 2013 S1; 95.2 S-0.3%, T-1.1% 91.4; 86.3–93.8
8 - Apr 2013 S1; 95.7 S-0.4%, T-1.8% 96.0; 93.6–97.7
9 - May 2014 S2; 76.7 S-0.5%, T-1.4% 98.3; 94.8–101.0
0.75 mg 10 - Oct 2014 S1; 0.0f S-62.3%, T-72.9%g 92.3; 72.9–126.5
11 - Dec 2014 S2; 77.0 S-0.2%, T-0.4% 100.4; 97.7–103.7
12 - Jul 2013 S1; 83.6 S-0.4%, T-1.2% 99.9; 95.0–105.6
13 - Sept 2015 S2; 77.8 S-0.2%, T-0.6% 99.3; 98.3–100.7
14a - June 2014 S1; 90.6 S-0.5%, T-1.6% 101.9; 100.1–104.7
14b - June 2014 S1; 88.3 S-0.5%, T-1.5% 102.0; 100.8–103.6
15 - Nov 2013 S1; 92.5 S-0.3%, T-1.3% 99.8; 93.2–105.3
16 - Sept 2013 S1; 89.5 S-0.4%, T-0.5% 102.5; 100.3–105.6
17 - Oct 2013 S1; 95.2 S-0.4%, T-2.0% 96.4; 71.5–115.1h
18 - Aug 2013 S1; 92.9 S-0.3%, T-1.3% 98.3; 94.2–103.3
19 - Nov 2013 S2; 79.8 S-0.3%, T-1.6% 101.7; 94.8–106.2
20 - Mar 2015 S1; 101.5 S-0.4%, T-1.5% 104.2; 99.8–116.4
aProduct Labels – number indicates a different brand, where a subsequent letter indicates a different batch. Bold text indicates non-compliance. With the exception of
2a, all samples yielded compliant results for identification (TLC and confirmation of levonorgestrel through the HPLC evaluation for dextronorgestrel). No sample
showed evidence of dextronorgestrel.
bDissolution presented with the stage required and average result.
cRelated Substances – the level of any single related substance (S) should be less than 1.0% and the total amount of related substances (T) should be less than 2.0%.
dAssay and Content Uniformity results presented as the average results and the minimum / maximum result found.
eOnly Stage 1 was conducted because 3 tablets were found to be below 60%.
fNo active release was observed on the 6 tablets tested. Additional tablets were tested for longer periods of release (1 hour) and observed ,2–5% release of active.
gA single peak was observed in the chromatogram (other than for levonorgestrel) which made a large contribution to the level of observed impurities.
h30 tablets tested.
doi:10.1371/journal.pone.0095353.t001
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fingerprint of the API (Figure 4b). These mass spectra matched
with those obtained for a levonorgestrel standard (Figures 4c and
4d, respectively). In contrast, the mass spectrum of sample 2a
exhibited the characteristic monoisotopic peak at m/z 254.0646
for the [sulfamethoxazole+H]+ ion (Dm=4.7 mDa), and a
completely different fingerprint was obtained from the product
ion mass spectrum of that precursor ion (Figures 4e and 4f). Both
isotopic and fragmentation patterns were identical to those
obtained for a sulfamethoxazole standard (Figures 4g and 4h),
further confirming the identity of the ingredient that substituted
levornorgestrel in sample 2a. This ambient MS technique
provided additional proof of the presence of sulfamethoxazole
through a fast and simple approach. Despite the different chemical
nature of levonorgestrel and sulfamethoxazole, both compounds
were easily ionized by both atmospheric pressure chemical
ionization and electrospray ionization mechanisms prevailing in
DART-MS and UHPLC-MS, respectively.
Once the identity of the wrong active ingredient in sample
2a was established beyond doubt, the concentration of
sulfamethoxazole was determined by UHPLC-QqQ-MS/MS.
Triple quadrupole mass spectrometers operated in multiple
reaction monitoring (MRM) mode minimize matrix interfer-
ences and chemical noise, making it a highly sensitive
approach for targeted quantitation. Optimized MRM param-
eters utilized for quantitation are listed in Table 2. The
254R92 precursor-to-product ion transition was used for
Figure 1. TLC analysis. Results for a levonorgestrel standard, sample
1 (positive control), and sample 2a observed under 254 nm light.
doi:10.1371/journal.pone.0095353.g001
Figure 2. HPLC-DAD analysis. HPLC chromatograms from assay / content uniformity analysis for a levonorgestrel standard, sample 1 (positive
control), and sample 2a.
doi:10.1371/journal.pone.0095353.g002
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sulfamethoxazole quantitation as it provided the highest
sensitivity; while the 254R156 transition was used for identity
confirmation. A six point external calibration curve
(R2 = 0.998) was used to determine sulfamethoxazole concen-
tration in sample 2a. The sulfamethoxazole quantity per tablet
was determined to be 2662 mg, equivalent to 1961% w/w.
Figure 3. UHPLC-IMS-TOF-MS analysis. Extracted ion chromatogram (A) and extracted ion mobility chronogram (B) for a levonorgestrel standard
with m/z 313.216860.005. Extracted ion chromatogram (C) and extracted ion mobility chronogram (D) for sulfamethoxazole standard with m/z
254.059960.005. Extracted ion chromatogram (E) and extracted ion mobility chronogram (F) for sulfamethoxazole in the poor quality contraceptive
tablet with m/z 254.059960.005. Mass spectra for the target compounds are displayed as insets.
doi:10.1371/journal.pone.0095353.g003
Figure 4. DART MS and MS/MS analysis using a collision energy of 20 eV. (A): Mass spectrum of a contraceptive tablet containing
levonorgestrel. (B): MS/MS spectrum for the precursor ion with m/z 313.2419 shown in A. (C): Mass spectrum of levonorgestrel standard. (D): MS/MS
spectrum for the precursor ion with m/z 313.2190 shown in C. (E): Mass spectrum of sample 2a. (F): MS/MS spectrum for the precursor ion with m/z
254.0646 shown in E. (G): Mass spectrum of sulfamethoxazole standard. (H): MS/MS spectrum for the precursor ion with m/z 254.0630 shown in G.
doi:10.1371/journal.pone.0095353.g004
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Further analysis was performed via 2D DOSY 1H NMR
spectroscopy to investigate the identity of excipients present in
sample 2a and compare those to what was present in authentic
samples with levonorgestrel from the same stated manufacturer.
2D DOSY 1H NMR has been successfully utilized in combination
with DART-MS for the investigation of falsified antimalarials [23].
Figure 5 shows the 2D DOSY 1H NMR spectra for the samples
dissolved in CD4O:D2O 80:20 v/v. Both samples presented two
soluble excipients that were identified as lactose (D,316 mm s21)
and magnesium stearate (D,407 mm s21); which are typically
found in pharmaceutical formulations [24]. Characteristic signals
in the 1H NMR spectrum of lactose included two doublets at 4.38
and 4.55 ppm associated with the protons of the disaccharide
anomeric carbons; a triplet at 3.22 ppm characteristic of the
proton bonded to the carbon involved in the glycosidic linkage in
the glucose moiety; and several signals between 3.48 and
3.92 ppm for the hydroxyls and remaining protons. Magnesium
stearate was evidenced by a main peak at 1.25 ppm, and signals at
0.87, 1.55 and 2.13 ppm. The confirmation of the identity of these
compounds was further assessed by comparison with standards
(Figures S1–S2). Although the principal ingredients exhibited
similar diffusion coefficients in both samples, the 1H NMR spectra
provided very different spectroscopic fingerprints both in terms of
chemical shifts and couplings characteristic of levonorgestrel
(D,436 mm s21) or sulfamethoxazole (D,446 mm s21). Charac-
teristic signals of sulfamethoxazole included two singlets at 2.3 and
6.05 ppm, and two doublets at 6.71 and 7.59 ppm, which clearly
do not overlap with any signal associated with levonorgestrel
(Figures S1–S3). In all spectra signals observed at 3.3 ppm and in
the range 4.6–5 ppm were due to the deuterated solvent mixture.
These experiments validated previous MS results by confirming
the presence of sulfamethoxazole in sample 2a, and provided a
further characterization of the sample in terms of excipients. In
this way, the analytical strategy based on different complimentary
techniques delivered a clear fingerprint of the composition of this
poor quality ECP.
Discussion
Levonorgestrel tablets for emergency contraception are cur-
rently available in two dosage forms, either one tablet of 1.5 mg or
two tablets each of 0.75 mg. Label instructions advise to use the
medication within 72 hours of unprotected intercourse, with the
second tablet taken 12 hours after the first one when using the
two-0.75 mg tablet dosage form. Whereas the 72-hour period is
the recommended timeframe for use, some evidence does suggest
that increased effectiveness is achieved when taken as soon as
possible, with moderate effectiveness provided from 72 to
120 hours after coitus [16,25]. When taken as instructed,
levonorgestrel tablets can reduce the risk of pregnancy by
approximately 80% (per ‘‘plan B’’ label, for example) relative to
the number of pregnancies that would be expected to occur with
unprotected intercourse [16,25,26]. This product type is only
effective when taken before ovulation [27,28].
Assuming that the in vitro dissolution method predicts the
expected in vivo release rate of the API, sample 10 may lead to little
to no contraceptive action due to the lack of levonorgestrel release.
Furthermore, the lower levels of levonorgestrel release for samples
2c, 3b, 4, and 6, with the wide range of tablet content found in
sample 17, suggest that these particular product batches may not
yield the full level of contraceptive effectiveness expected,
especially considering the suggested importance of taking the
medication in a timely manner after intercourse but before
ovulation [16,25,26]. Only 72% of the batches analyzed in the
present market survey would be expected to provide the stated
level of contraceptive action. Of the remaining batches, 20%
would be expected to provide questionable results (samples 2c, 3b,
4, 6, 17), with 8% offering little to no prevention against unwanted
pregnancy (samples 2a and 10).
Sample 2a would present the highest risk to the consumer due to
the lack of expected contraceptive action and the potential
complications that may arise from the presence of sulfamethox-
azole. Sulphonamide antibiotics have been found before as wrong
active ingredients in falsified medicines, as is the case of
sulfamethoxazole and sulfadoxine in falsified artesunate [29].
Sulphonamides have a wide range of adverse effects, such as rash
and Stevens-Johnson syndrome, and may also interact with other
commonly-used medicines. Without the patient’s or health
workers awareness of sulpha medicine consumption, any adverse
effects or interactions would be clinically very confusing.
Following the identification of sulfamethoxazole in sample 2a,
the Peruvian medicine regulatory authority, DIGEMID (Direc-
cio´n General de Medicamentos Insumos y Drogas), was informed
[30,31]. Additionally, the manufacturer indicated on the packag-
ing for sample 2a was contacted regarding these results. The
manufacturer indicated that their facilities dedicated to the
production of hormonal contraceptives are separated from the
facilities used in the manufacturing of other pharmaceuticals, thus
preventing the risk of contamination. The manufacturer also
stated that a local distributor in Peru had reported to DIGEMID
that the entire stock of the original sample of 2a had been stolen,
thus raising suspicion that sample 2a is fraudulent. Furthermore,
the distributor had also alerted DIGEMID about fraudulent
samples of product 2b on the market, providing genuine and
fraudulent samples of 2b to DIGEMID for further investigation.
Although we obtained what apparently is a genuine sample of 2b,
the results obtained for 2c are leading the manufacturer to
investigate the possibility of fraudulent 2c product.
The detection and comprehensive characterization of falsified
pharmaceuticals can provide critical information that contributes
to avoid severe consequences to the patient. Here, we have proven
that the combination of two different mass spectrometric-based
methods that utilized chromatographic and ion mobility separa-
tions, and ambient ionization techniques allowed the identification
of the unknown wrong API in the batch suspected to be
fraudulent, and a third mass spectrometric-based method provided
successful quantitation of the drug in the poor quality ECP. As
Table 2. Precursor ion, fragmentor voltage, collision cell voltage, and product ions for sulfamethoxazole MRM analysis.
Analyte Precursor Ions (m/z) Fragmentor Voltage/V Collision cell Voltage/V Product Ions (m/z)
Sulfamethoxazole [M+H]+ 254 122 28 92Q
254 122 12 156C
QQuantifying ion; C Confirming ion.
doi:10.1371/journal.pone.0095353.t002
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well, qualitative characterization in terms of excipients was
accomplished by means of 2D DOSY 1H NMR spectroscopy.
Therefore, a multi-platform analytical strategy based on sophis-
ticated complimentary techniques can provide exhaustive charac-
terization of falsified medicines and becomes crucial in the
screening of poor quality medicines.
Overall, these results highlight the diversity of drug quality
problems that have important implications for public health, and
especially women’s health and society. These ranged from
inadequate amount and release of levonorgestrel to the presence
of a wrong active ingredient. This work also emphasizes the need
for efficient oversight of pharmaceutical products, with proper
monitoring of manufacturers and distribution mechanisms (with
proper storage and supply chain security) in order to lower the risk
of users being exposed to products of poor quality, safety, and
efficacy. The fact that falsified emergency contraception has been
reported in Nigeria, Ghana, Kenya, Angola and USA [15] and
now South America is also known to be afflicted, suggests that it is
an important and widespread public health problem. The WHO
has been conducting a prequalification program for pharmaceu-
ticals which historically has placed a significant emphasis on HIV,
malaria and tuberculosis medications, with growing effort for
reproductive health products [32]. Currently there are three
products WHO prequalified for emergency contraception. Hope-
fully, resources will be allocated for additional prequalification of
ECPs to provide further assistance for improving and assuring
product quality in the global market for this important class of
products. The fact that even pre-qualified emergency contracep-
tion products have been targeted by counterfeiters in Africa [15]
strongly suggests that more resources should be invested in
checking the medicine supply.
Conclusions
The chemical quality of emergency contraceptives (0.75 mg and
1.5 mg levonorgestrel tablets) in Lima, Peru, was evaluated. Of the
25 different batches analyzed, 7 batches were non-complaint with
product specifications; mainly due to inadequate levonorgestrel
dissolution. The most striking result was provided by a batch that
contained a wrong active ingredient with no levonorgestrel
detected. Mass spectrometry and 2D DOSY 1H NMR spectros-
copy identified the unknown compound as the antibiotic
sulfamethoxazole. Government authorities in Peru and the stated
manufacturer were alerted of the findings for further investigation
of the source of this product.
Supporting Information
Figure S1 1H NMR spectra. a) genuine ECP, b) levonorges-
trel standard; c) lactose standard; d) Mg stearate standard dissolved
in CD4O:D2O (80:20 v/v). Signals observed at 3.3 ppm and in
the range 4.6–5 ppm are due to the solvent.
(TIF)
Figure S2 1H NMR spectra. a) sample 2a, b) sulfamethoxa-
zole standard; c) lactose standard; d) Mg stearate standard
dissolved in CD4O:D2O (80:20 v/v). Signals observed at
3.3 ppm and in the range 4.6–5 ppm are due to the solvent.
(TIF)
Figure S3 1H NMR spectra. Genuine (top) and poor quality
(bottom) contraceptive tablet dissolved in CD4O:D2O (80:20 v/v).
Signals observed at 3.3 ppm and in the range 4.6–5 ppm are due
to the solvent.
(TIF)
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